Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800874 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL780400 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL800400 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL23710670 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL23200376 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL23710671 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL23200375 | 0.89 | TAAR1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL1527362 | 0.88 | NT5E (0.59) | HINT1TAAR1NT5ESTING1PDE3B | |
| SCHEMBL18954813 | 0.88 | HINT1 (0.44) | HINT1TAAR1NT5E | |
| SCHEMBL7535718 | 0.87 | HINT1 (0.58) | HINT1TAAR1NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 672 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| CN-114373510-B | Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023083197-A1 | METABOLIC MARKER FOR DIAGNOSING OR MONITORING LUNG CANCER, AND SCREENING METHOD THEREFOR AND USE THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-05-19 | — | — | WO | claimed |
| CN-115487542-A | Solid-phase extraction method for modified nucleosides in urine and application of solid-phase extraction method | 浙江大学 | 2022-12-20 | — | — | CN | claimed |
| CN-109425670-B | Method for detecting fatigue degree of team based on human urine | 中国民用航空局民用航空医学中心 | 2022-09-16 | — | — | CN | claimed |
| CN-109425669-B | Method for screening biomarkers related to fatigue degree in human body fluid by liquid chromatography-mass spectrometry | 中国民用航空局民用航空医学中心 | 2022-09-16 | — | — | CN | claimed |
| CN-114373510-A | Metabolic marker for lung cancer diagnosis or monitoring and screening method and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| WO-2022075354-A1 | A METHOD FOR OBTAINING AN INDEX FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (AD) | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2022-04-14 | — | — | WO | claimed |
| US-20210317496-A1 | Methods and Compositions for Increased Capping Efficiency of Transcribed RNA | NEW ENGLAND BIOLABS, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3861108-A1 | METHODS AND COMPOSITIONS FOR INCREASING CAPPING EFFICIENCY OF TRANSCRIBED RNA | New England Biolabs, Inc. (US) | 2021-08-11 | — | — | EP | claimed |
| WO-2013177222-A1 | METABOLITE BIOMARKERS FOR THE DETECTION OF LIVER CANCER | PURDUE RESEARCH FOUNDATION (US) | 2013-11-28 | — | — | WO | claimed |
| EP-2547379-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | Fresenius Medical Care Deutschland GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20130011364-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2013-01-10 | — | — | US | claimed |
| US-20120107955-A1 | METABOLITE BIOMARKERS FOR THE DETECTION OF ESOPHAGEAL CANCER USING MS | PURDUE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | claimed |
| WO-2011113607-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| WO-2001085220-A1 | LABELED NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | RNA-TEC N.V. (BE) | 2001-11-15 | — | — | WO | claimed |
| US-20010021772-A1 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-13 | — | — | US | claimed |
| EP-1100894-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-23 | — | — | EP | claimed |
| WO-2000008141-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | claimed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | HINT1 1114/4885TAAR1 2255/4885NT5E 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.